NCT03099538View on ClinicalTrials.gov

Ixekizumab in the Treatment of Bullous Pemphigoid

PHASE2CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

June 6, 2019

Study Completion Date

June 6, 2019

Conditions

Bullous PemphigoidPemphigoid

Interventions

DRUG

Ixekizumab

Subcutaneous injection

Trial Locations (1)

85259

Mayo Clinic, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Mayo Clinic

OTHER

NCT03099538 - Ixekizumab in the Treatment of Bullous Pemphigoid | Biotech Hunter | Biotech Hunter